Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics entities : Regeneron pharmaceuticals, inc. save search
Monoclonal Antibody (mABs) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
Published: 2024-03-15 (Crawled : 14:30) - prnewswire.com
TAK | News | $13.16 0.08% 0.53% 1.2M
|
Health Technology
|
| O: 0.21%
H: 0.97%
C: 0.7%
NVS | $92.57 -0.55% 0.27% 840K
|
Health Technology
|
| O: 0.05%
H: 0.14%
C: -0.93%
JNJ | News | $145.74 0.67% -0.18% 7M
|
Health Technology
|
| O: -1.58%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.7%
H: 0.73%
C: -0.16%
ABBV | News | $164.66 0.25% -0.14% 3.6M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
REGN | $893.99 -0.8% -0.84% 450K
|
Health Technology
|
| O: -0.27%
H: 1.26%
C: 0.84%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: 0.2%
H: 1.14%
C: -1.18%
antibody therapeutics market
Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones
Published: 2024-01-04 (Crawled : 21:00) - globenewswire.com
REGN | $893.99 -0.8% -0.84% 450K
|
Health Technology
|
| O: -0.79%
H: 1.96%
C: 0.9%
NTLA | $21.32 -0.84% -0.94% 900K
|
Health Technology
|
| O: -2.34%
H: 0.45%
C: -0.69%
therapeutics
Antibody Therapeutics Market Worth $479.0 Billion | MarketsandMarkets
Published: 2023-12-07 (Crawled : 15:30) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.66%
H: 0.0%
C: 0.0%
NVS | $92.57 -0.55% 0.27% 840K
|
Health Technology
|
| O: -0.97%
H: 0.3%
C: -0.19%
JNJ | News | $145.74 0.67% -0.18% 7M
|
Health Technology
|
| O: -1.61%
H: 0.0%
C: 0.0%
ABBV | News | $164.66 0.25% -0.14% 3.6M
|
Health Technology
|
| O: 1.97%
H: 0.0%
C: 0.0%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -1.19%
H: 0.0%
C: 0.0%
REGN | $893.99 -0.8% -0.84% 450K
|
Health Technology
|
| O: 0.51%
H: 1.22%
C: 1.09%
IMNM | $17.18 -1.15% -1.19% 810K
|
Health Technology
|
| O: -0.64%
H: 1.67%
C: -1.16%
BIIB | $190.52 -0.85% -0.84% 1.3M
|
Health Technology
|
| O: 1.67%
H: 0.91%
C: 0.57%
antibody therapeutics market
Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Published: 2023-11-09 (Crawled : 12:30) - globenewswire.com
REGN | $893.99 -0.8% -0.84% 450K
|
Health Technology
|
| O: -0.89%
H: 0.15%
C: -1.87%
NTLA | $21.32 -0.84% -0.94% 900K
|
Health Technology
|
| O: 0.18%
H: 0.67%
C: -12.42%
company therapeutics financial results
Regeneron Reports Third Quarter 2023 Financial and Operating Results
Published: 2023-11-02 (Crawled : 11:00) - globenewswire.com
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 3.0%
H: 0.0%
C: 0.0%
REGN | $893.99 -0.8% -0.84% 450K
|
Health Technology
|
| O: 0.08%
H: 4.96%
C: 3.4%
NTLA | $21.32 -0.84% -0.94% 900K
|
Health Technology
|
| O: 2.35%
H: 1.63%
C: 1.46%
ALNY | News | $145.16 -0.11% -0.19% 400K
|
Health Technology
|
| O: 3.4%
H: 0.57%
C: -0.5%
financial results
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
Published: 2023-10-03 (Crawled : 11:00) - globenewswire.com
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -1.41%
H: 0.0%
C: 0.0%
REGN | $893.99 -0.8% -0.84% 450K
|
Health Technology
|
| O: -0.74%
H: 0.21%
C: -0.45%
NTLA | $21.32 -0.84% -0.94% 900K
|
Health Technology
|
| O: -0.1%
H: 1.97%
C: 1.02%
treatment research collaboration neurological
Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss
Published: 2023-09-25 (Crawled : 13:00) - globenewswire.com
PPRUF | News | $358.55 -0.93% 37.56% 1.5K
|
Consumer Non-Durables
|
| O: -3.71%
H: 0.0%
C: -0.92%
PPRUY | News | $36.0023 -0.08% -0.11% 220K
|
Manufacturing
|
| O: -4.65%
H: 0.53%
C: -0.02%
REGN | $893.99 -0.8% -0.84% 450K
|
Health Technology
|
| O: -0.22%
H: 1.43%
C: 1.41%
acquisition therapy
Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs
Published: 2023-08-09 (Crawled : 12:00) - globenewswire.com
PPRUF | News | $358.55 -0.93% 37.56% 1.5K
|
Consumer Non-Durables
|
| O: 1.36%
H: 3.13%
C: 2.6%
PPRUY | News | $36.0023 -0.08% -0.11% 220K
|
Manufacturing
|
| O: 0.62%
H: 0.32%
C: -0.47%
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: 74.36%
H: 0.0%
C: 0.0%
REGN | $893.99 -0.8% -0.84% 450K
|
Health Technology
|
| O: 1.9%
H: 0.0%
C: 0.0%
acquire therapy
Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
Published: 2023-08-03 (Crawled : 12:00) - globenewswire.com
REGN | $893.99 -0.8% -0.84% 450K
|
Health Technology
|
| O: 2.72%
H: 3.39%
C: 1.24%
NTLA | $21.32 -0.84% -0.94% 900K
|
Health Technology
|
| O: -3.48%
H: 2.74%
C: 1.98%
therapeutics financial results
Melanoma Market to Witness Promising Growth, Predicts DelveInsight | Key Companies To Watch - IO Biotech, Merck, Eisai, Regeneron, Genentech, Seagen, Amgen, Astellas, Galectin, MedImmune, Aivita, Linnaeus, Checkmate, OnKure
Published: 2023-06-12 (Crawled : 15:00) - prnewswire.com
PVCT | News 4 | $0.195 2.63% -15.0% 56K
|
Manufacturing
|
| O: -7.85%
H: 9.72%
C: 8.25%
ALPMY | $9.47 0.11% -1.11% 520K
|
Manufacturing
|
| O: -0.68%
H: 3.23%
C: 1.55%
XNCR | $18.95 -0.63% -0.47% 470K
|
Health Technology
|
| O: 0.33%
H: 1.45%
C: 0.59%
REGN | $893.99 -0.8% -0.84% 450K
|
Health Technology
|
| O: 0.18%
H: 0.91%
C: 0.83%
NKTR | $1.32 -2.22% -3.85% 2.4M
|
Health Technology
|
| O: 0.0%
H: 1.45%
C: -3.33%
IDYA | $37.62 -6.35% -6.75% 850K
|
Health Technology
|
| O: 0.47%
H: 2.93%
C: -1.6%
GALT | $3.38 -0.6% 150K
|
Health Technology
|
| O: -0.66%
H: 3.97%
C: -3.31%
BNTX | $86.17 -0.27% -0.24% 520K
|
Health Technology
|
| O: -0.68%
H: 1.97%
C: 1.18%
melanoma companies market
Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO
Published: 2023-05-12 (Crawled : 11:00) - globenewswire.com
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: 0.84%
H: 6.94%
C: 0.28%
REGN | $893.99 -0.8% -0.84% 450K
|
Health Technology
|
| O: 0.48%
H: 0.36%
C: -0.64%
candidate approval medical application trial therapeutics therapy
Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
Published: 2023-05-04 (Crawled : 11:00) - globenewswire.com
REGN | $893.99 -0.8% -0.84% 450K
|
Health Technology
|
| O: -3.44%
H: 0.13%
C: -2.79%
NTLA | $21.32 -0.84% -0.94% 900K
|
Health Technology
|
| O: 0.47%
H: 14.06%
C: 12.62%
therapeutics financial results
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-04-26 (Crawled : 23:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: 0.0%
REGN | $893.99 -0.8% -0.84% 450K
|
Health Technology
|
| O: -0.99%
H: 0.38%
C: -0.48%
ALNY | News | $145.16 -0.11% -0.19% 400K
|
Health Technology
|
| O: -0.76%
H: 0.33%
C: -1.54%
disease report alzheimer’s positive
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-04-26 (Crawled : 23:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: 0.0%
REGN | $893.99 -0.8% -0.84% 450K
|
Health Technology
|
| O: -0.99%
H: 0.38%
C: -0.48%
ALNY | News | $145.16 -0.11% -0.19% 400K
|
Health Technology
|
| O: -0.76%
H: 0.33%
C: -1.54%
disease report alzheimer’s positive
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress
Published: 2023-02-23 (Crawled : 14:00) - biospace.com/
REGN | $893.99 -0.8% -0.84% 450K
|
Health Technology
|
| O: -0.44%
H: 2.71%
C: 1.99%
NTLA | $21.32 -0.84% -0.94% 900K
|
Health Technology
|
| O: 4.7%
H: 0.0%
C: -4.42%
therapeutics financial results
Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
Published: 2023-02-03 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -5.75%
H: 0.0%
C: 0.0%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -4.01%
H: 0.0%
C: 0.0%
REGN | $893.99 -0.8% -0.84% 450K
|
Health Technology
|
| O: 1.77%
H: 3.33%
C: 2.44%
CTMX | $1.73 -1.7% -1.44% 200K
|
Health Technology
|
| O: 0.39%
H: 4.23%
C: 1.92%
ACET | $2.025 -10.79% -12.38% 930K
|
Health Technology
|
| O: -1.63%
H: 1.98%
C: -3.52%
year financial results
Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
Published: 2023-01-24 (Crawled : 13:20) - biospace.com/
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: -0.15%
H: 18.49%
C: 15.32%
REGN | $893.99 -0.8% -0.84% 450K
|
Health Technology
|
| O: 0.15%
H: 0.18%
C: -0.48%
candidate application trial approval therapeutics therapy
Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence
Published: 2023-01-19 (Crawled : 13:20) - globenewswire.com
REGN | $893.99 -0.8% -0.84% 450K
|
Health Technology
|
| O: 0.67%
H: 0.08%
C: -1.89%
OTLK P | $8.29 -3.72% -3.92% 220K
|
Health Technology
|
| O: -1.61%
H: 4.92%
C: -1.64%
BIIB | $190.52 -0.85% -0.84% 1.3M
|
Health Technology
|
| O: -0.73%
H: 1.05%
C: -0.45%
therapeutics commercial medical
Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones
Published: 2023-01-05 (Crawled : 13:00) - biospace.com/
REGN | $893.99 -0.8% -0.84% 450K
|
Health Technology
|
| O: -0.25%
H: 0.81%
C: -0.13%
NTLA | $21.32 -0.84% -0.94% 900K
|
Health Technology
|
| O: -1.3%
H: 2.05%
C: 0.44%
therapeutics
Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop
Published: 2022-12-19 (Crawled : 14:00) - biospace.com/
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.57%
H: 0.53%
C: -0.01%
REGN | $893.99 -0.8% -0.84% 450K
|
Health Technology
|
| O: -0.3%
H: 0.72%
C: 0.02%
potential
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
TPET | $0.3279 -3.56% 28.48% 33M
|
n/a
GDHG | $0.263 21.76% 25.34% 1.3M
|
HOLO | $2.95 31.7% 22.49% 37M
|
UMAC | $1.55 0.65% 16.13% 3K
|
MTNB | $0.19 -1.04% 14.58% 950K
|
Health Technology
VLD 4 | $0.2638 -3.65% 13.27% 2.6M
|
Manufacturing
ALLR | $1.54 2.67% 11.76% 740K
|
n/a
MGLD 4 | $1.13 5.61% 10.62% 200
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.